Drugs for treating autoimmune diseases led the German biopharmaceutical market in revenue and growth in 2018. Not only do biopharmaceuticals make a significant contribution to economy, they offer a multitude of benefits for patients and support society as a whole. Autoimmune diseases are caused by a malfunctioning immune system and encompass diseases like multiple sclerosis, rheumatoid arthritis and acquired thrombotic thrombocytopenic purpura. Biopharmaceuticals are vital to the treatment of autoimmune diseases as they provide a targeted and effective means of therapy. This is central to the alleviation of disease symptoms and patient discomfort. In addition, biopharmaceuticals are not only known to halt progression of autoimmune diseases, but they can even occasionally reverse it.
Biopharmaceutical treatments are known to significantly improve patient wellbeing, and hence their quality of life. The introduction and steady development of devices has also been instrumental in improving patient experience, by simplifying regular drug administration. An equally important role in ensuring patient compliance to the course of treatment is played by patient support programs. Together, these translate to reducing dropout rates and ensuring adherence to the therapeutic program. In the long run, biopharmaceuticals present significant benefits to patients, society and economy. Dr. Frank Mathias, CEO and Dr. Latika Bhonsle-Deeng, Manager Corporate Communication present the various benefits of biopharmaceuticals, for patients with autoimmune diseases, in the October Issue of Pharmind.
For more details please click here.
Rentschler Biopharma SE
Dr. Cora Kaiser
Senior Director Corporate Communication